What is coronary artery calcium (CAC) and how does the CAC score guide assessment of subclinical atherosclerosis in a 34‑year‑old patient with markedly elevated lipoprotein(a)?

What is CAC and How Does It Guide Assessment in a 34-Year-Old with Elevated Lp(a)?

CAC (Coronary Artery Calcium) is a CT-based measurement that quantifies calcium deposits in coronary arteries, serving as a highly specific marker of subclinical atherosclerosis and a powerful predictor of future cardiovascular events. 1

Understanding CAC

CAC is measured using electrocardiogram-gated multidetector CT scanning that quantifies calcified plaque burden using the Agatston scoring system 1. The test:

• Requires minimal radiation exposure (0.37 ± 0.16 mSv—less than a screening mammogram) 1
• Identifies calcified lesions with CT density >130 Hounsfield units and area >1 mm² 1
• Represents approximately 20% of total atherosclerotic plaque burden (not all plaques calcify) 1
• Functions as a marker of atherosclerosis presence and burden, NOT degree of stenosis 1

CAC Score Interpretation

The scoring categories directly correlate with cardiovascular risk 1:

• CAC = 0: Very low risk (<1% annual cardiac death/MI); excellent prognosis with event rate 0.16%/year 1
• CAC 1-100: Low risk (<10% at 10 years) 2
• CAC 101-400: Intermediate risk (10-20% at 10 years) 2
• CAC >400: High risk (>20% at 10 years); ACC/AHA recommends screening for silent ischemia at this threshold 1

Application in Your 34-Year-Old Patient with Elevated Lp(a)

This clinical scenario presents a unique challenge because elevated Lp(a) increases risk through both calcified AND noncalcified plaque mechanisms 3. Here's the evidence-based approach:

The Lp(a)-CAC Relationship

Recent multicohort data demonstrates that elevated Lp(a) (>50 mg/dL) confers increased cardiovascular risk across ALL CAC strata, including CAC = 0 3. Specifically:

• Among individuals with CAC = 0, those with Lp(a) >50 mg/dL had higher event rates (4.9 vs 3.8/1,000 person-years; HR 1.28) 3
• Among those with CAC >0, elevated Lp(a) further increased risk (21.2 vs 18.2/1,000 person-years; HR 3.03) 3
• The highest risk group had both CAC ≥300 AND Lp(a) >50 mg/dL (HR 6.12) 3
• Importantly, absolute event rates remained low even with elevated Lp(a) when CAC = 0 3

Age-Specific Considerations

At age 34, your patient falls outside the typical CAC screening age range (40-75 years) recommended by major guidelines 1. However, the 2017 SCCT consensus states CAC is appropriate for "selected low-risk adults with a family history of premature CAD" 1.

Elevated Lp(a) is associated with increased CAC presence and progression, though with notable variability 4, 5. In asymptomatic patients, high Lp(a) (≥50 mg/dL) was significantly associated with advanced CAC (≥400 AU) with adjusted OR 1.666 5.

Clinical Decision Algorithm for This Patient

1. Assess Traditional Risk Factors First

• Calculate 10-year ASCVD risk using pooled cohort equations
• Document family history of premature CAD
• Quantify Lp(a) level precisely

2. Consider CAC Testing If:

• Uncertainty exists about initiating preventive therapy (particularly statins)
• Patient has additional risk factors beyond Lp(a) (family history, metabolic syndrome, diabetes)
• Only proceed if results will change management decisions 2

3. Interpret Results in Context:

• If CAC = 0: Provides reassurance that absolute risk remains low despite elevated Lp(a); focus on aggressive lifestyle modification and consider statin therapy based on overall risk profile 3, 6

• If CAC 1-99: Confirms early atherosclerosis; initiate pharmacologic prevention with statin therapy 6

• If CAC 100-299: Higher-risk plaque requiring intensive lipid-lowering therapy; consider adjunctive therapies 6

• If CAC ≥300: Approaches secondary prevention risk phenotype; aggressive multi-drug lipid-lowering strategy warranted 6

Critical Caveats

The "power of zero" applies even with elevated Lp(a), but absolute risk is still higher than those with normal Lp(a) 3. A zero CAC score does not eliminate the need for risk factor modification in someone with markedly elevated Lp(a).

CAC testing should NOT be repeated within 5 years if initial score is zero 2. For positive scores, routine re-scanning is not currently recommended, though annual increases >15% or >100 units predict future events 2.

Patient counseling before testing is essential: Discuss that CAC results will guide intensity of preventive therapy, including potential lifelong statin use. The test is typically not covered by insurance and costs are patient-borne 2.

Management Framework

Regardless of CAC score, all patients with elevated Lp(a) require:

• Optimal diet and lifestyle measures (foundation of prevention) 2
• Aggressive LDL-C lowering (target <70 mg/dL, potentially <55 mg/dL if CAC present)
• Consideration of emerging Lp(a)-lowering therapies in very high-risk scenarios (CAC ≥300 + Lp(a) >50 mg/dL) 4

CAC scoring remains a powerful tool for risk stratification in individuals with elevated Lp(a), enabling personalized prevention strategies that align treatment intensity with actual plaque burden 7, 3, 8.